Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non-Small Cell Lung Cancer Patients.

Lusk CM, Watza D, Dyson G, Craig D, Ratliff V, Wenzlaff AS, Lonardo F, Bollig-Fischer A, Bepler G, Purrington K, Gadgeel S, Schwartz AG.

Clin Cancer Res. 2019 Jul 15;25(14):4300-4308. doi: 10.1158/1078-0432.CCR-18-2439. Epub 2019 Apr 12.

PMID:
30979741
2.

Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells.

Teslow EA, Mitrea C, Bao B, Mohammad RM, Polin LA, Dyson G, Purrington KS, Bollig-Fischer A.

Mol Oncol. 2019 Apr;13(4):894-908. doi: 10.1002/1878-0261.12444. Epub 2019 Mar 1.

3.

Exogenous IL-6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells.

Teslow EA, Bao B, Dyson G, Legendre C, Mitrea C, Sakr W, Carpten JD, Powell I, Bollig-Fischer A.

Mol Oncol. 2018 Jun;12(7):1138-1152. doi: 10.1002/1878-0261.12316. Epub 2018 May 24.

4.

Racial Disparities in the Molecular Landscape of Cancer.

Heath EI, Lynce F, Xiu J, Ellerbrock A, Reddy SK, Obeid E, Liu SV, Bollig-Fischer A, Separovic D, Vanderwalde A.

Anticancer Res. 2018 Apr;38(4):2235-2240.

5.

Integrating 5hmC and gene expression data to infer regulatory mechanisms.

Mitrea C, Wijesinghe P, Dyson G, Kruger A, Ruden DM, Draghici S, Bollig-Fischer A.

Bioinformatics. 2018 May 1;34(9):1441-1447. doi: 10.1093/bioinformatics/btx777.

6.

Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.

Bao B, Mitrea C, Wijesinghe P, Marchetti L, Girsch E, Farr RL, Boerner JL, Mohammad R, Dyson G, Terlecky SR, Bollig-Fischer A.

Sci Rep. 2017 Mar 10;7:44125. doi: 10.1038/srep44125.

7.

How the future of clinical cancer diagnostics can contribute to overcoming race-associated cancer disparities.

Bollig-Fischer A.

Expert Rev Mol Diagn. 2016 Dec;16(12):1233-1235. Epub 2016 Nov 11. No abstract available.

PMID:
27792413
8.

Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.

Wijesinghe P, Bollig-Fischer A.

Adv Exp Med Biol. 2016;890:1-23. doi: 10.1007/978-3-319-24932-2_1. Review.

PMID:
26703796
9.

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.

Azmi AS, Muqbil I, Wu J, Aboukameel A, Senapedis W, Baloglu E, Bollig-Fischer A, Dyson G, Kauffman M, Landesman Y, Shacham S, Philip PA, Mohammad RM.

Sci Rep. 2015 Nov 5;5:16077. doi: 10.1038/srep16077.

10.

Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.

Ahmad A, Ginnebaugh KR, Yin S, Bollig-Fischer A, Reddy KB, Sarkar FH.

BMC Cancer. 2015 Jul 24;15:540. doi: 10.1186/s12885-015-1561-x.

11.

In Response.

Bollig-Fischer A.

J Thorac Oncol. 2015 Aug;10(8):e77-8. doi: 10.1097/JTO.0000000000000596. No abstract available.

12.

Development of patient-derived xenograft models from a spontaneously immortal low-grade meningioma cell line, KCI-MENG1.

Michelhaugh SK, Guastella AR, Varadarajan K, Klinger NV, Parajuli P, Ahmad A, Sethi S, Aboukameel A, Kiousis S, Zitron IM, Ebrahim SA, Polin LA, Sarkar FH, Bollig-Fischer A, Mittal S.

J Transl Med. 2015 Jul 15;13:227. doi: 10.1186/s12967-015-0596-8.

13.

Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics.

Bollig-Fischer A, Michelhaugh SK, Wijesinghe P, Dyson G, Kruger A, Palanisamy N, Choi L, Alosh B, Ali-Fehmi R, Mittal S.

Oncotarget. 2015 Jun 10;6(16):14614-24.

14.

(-)-Epicatechin combined with 8 weeks of treadmill exercise is associated with increased angiogenic and mitochondrial signaling in mice.

Lee I, Hüttemann M, Kruger A, Bollig-Fischer A, Malek MH.

Front Pharmacol. 2015 Mar 13;6:43. doi: 10.3389/fphar.2015.00043. eCollection 2015.

15.

Two members of the TRiC chaperonin complex, CCT2 and TCP1 are essential for survival of breast cancer cells and are linked to driving oncogenes.

Guest ST, Kratche ZR, Bollig-Fischer A, Haddad R, Ethier SP.

Exp Cell Res. 2015 Mar 15;332(2):223-35. doi: 10.1016/j.yexcr.2015.02.005. Epub 2015 Feb 20.

PMID:
25704758
16.

Considering race and the potential for ERG expression as a biomarker for prostate cancer.

Powell IJ, Dyson G, Chinni SR, Bollig-Fischer A.

Per Med. 2014;11(4):409-412.

17.

A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.

Wijesinghe P, Bepler G, Bollig-Fischer A.

J Thorac Oncol. 2015 Feb;10(2):381-6. doi: 10.1097/JTO.0000000000000337.

18.

Racial diversity of actionable mutations in non-small cell lung cancer.

Bollig-Fischer A, Chen W, Gadgeel SM, Wenzlaff AS, Cote ML, Schwartz AG, Bepler G.

J Thorac Oncol. 2015 Feb;10(2):250-5. doi: 10.1097/JTO.0000000000000420.

19.

Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.

Madden JM, Mueller KL, Bollig-Fischer A, Stemmer P, Mattingly RR, Boerner JL.

Breast Cancer Res Treat. 2014 Sep;147(2):283-93. doi: 10.1007/s10549-014-3102-8. Epub 2014 Aug 17.

20.

Modeling time-dependent transcription effects of HER2 oncogene and discovery of a role for E2F2 in breast cancer cell-matrix adhesion.

Bollig-Fischer A, Marchetti L, Mitrea C, Wu J, Kruger A, Manca V, Drăghici S.

Bioinformatics. 2014 Nov 1;30(21):3036-43. doi: 10.1093/bioinformatics/btu400. Epub 2014 Jul 15.

21.

Amyloid-beta neuroprotection mediated by a targeted antioxidant.

Giordano CR, Terlecky LJ, Bollig-Fischer A, Walton PA, Terlecky SR.

Sci Rep. 2014 May 15;4:4983. doi: 10.1038/srep04983.

22.

Modeling the sustainability of community health networks: novel approaches for analyzing collaborative organization partnerships across time.

Manning MA, Bollig-Fischer A, Bobovski LB, Lichtenberg P, Chapman R, Albrecht TL.

Transl Behav Med. 2014 Mar;4(1):46-59. doi: 10.1007/s13142-013-0220-5.

23.

Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR.

Gadgeel SM, Chen W, Cote ML, Bollig-Fischer A, Land S, Schwartz AG, Bepler G.

PLoS One. 2013 Nov 8;8(11):e79820. doi: 10.1371/journal.pone.0079820. eCollection 2013.

24.

Intronic non-CG DNA hydroxymethylation and alternative mRNA splicing in honey bees.

Cingolani P, Cao X, Khetani RS, Chen CC, Coon M, Sammak A, Bollig-Fischer A, Land S, Huang Y, Hudson ME, Garfinkel MD, Zhong S, Robinson GE, Ruden DM.

BMC Genomics. 2013 Sep 30;14:666. doi: 10.1186/1471-2164-14-666.

25.

Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25.

Azmi AS, Bollig-Fischer A, Bao B, Park BJ, Lee SH, Yong-Song G, Dyson G, Reddy CK, Sarkar FH, Mohammad RM.

BMC Syst Biol. 2013 Sep 3;7:85. doi: 10.1186/1752-0509-7-85.

26.

Minireview: the molecular and genomic basis for prostate cancer health disparities.

Powell IJ, Bollig-Fischer A.

Mol Endocrinol. 2013 Jun;27(6):879-91. doi: 10.1210/me.2013-1039. Epub 2013 Apr 22. Review.

27.

The molecular genomics of metastatic brain tumours.

Bollig-Fischer A, Michelhaugh S, Ali-Fehmi R, Mittal S.

OA Mol Oncol. 2013 Apr 1;1(1). pii: https://www.oapublishinglondon.com/article/759#.

28.

Genes associated with prostate cancer are differentially expressed in African American and European American men.

Powell IJ, Dyson G, Land S, Ruterbusch J, Bock CH, Lenk S, Herawi M, Everson R, Giroux CN, Schwartz AG, Bollig-Fischer A.

Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):891-7. doi: 10.1158/1055-9965.EPI-12-1238. Epub 2013 Mar 20.

29.

A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.

Giordano CR, Mueller KL, Terlecky LJ, Krentz KA, Bollig-Fischer A, Terlecky SR, Boerner JL.

Exp Cell Res. 2012 Oct 1;318(16):2014-21. doi: 10.1016/j.yexcr.2012.06.001. Epub 2012 Jun 8.

31.

Oncogene activation induces metabolic transformation resulting in insulin-independence in human breast cancer cells.

Bollig-Fischer A, Dewey TG, Ethier SP.

PLoS One. 2011 Mar 17;6(3):e17959. doi: 10.1371/journal.pone.0017959.

32.

Transforming properties of 8p11-12 amplified genes in human breast cancer.

Yang ZQ, Liu G, Bollig-Fischer A, Giroux CN, Ethier SP.

Cancer Res. 2010 Nov 1;70(21):8487-97. doi: 10.1158/0008-5472.CAN-10-1013. Epub 2010 Oct 12.

33.

HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.

Bollig-Fischer A, Dziubinski M, Boyer A, Haddad R, Giroux CN, Ethier SP.

Cancer Res. 2010 Oct 15;70(20):7862-73. doi: 10.1158/0008-5472.CAN-10-1529. Epub 2010 Aug 24.

34.

Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.

Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP, Yang ZQ.

Oncogene. 2009 Dec 17;28(50):4491-500. doi: 10.1038/onc.2009.297. Epub 2009 Sep 28.

35.

Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers.

Yang ZQ, Liu G, Bollig-Fischer A, Haddad R, Tarca AL, Ethier SP.

Int J Cancer. 2009 Oct 1;125(7):1613-21. doi: 10.1002/ijc.24518.

Supplemental Content

Loading ...
Support Center